cancer

Innovation Awards Spark New Intramural Collaborations

Program Boosts Initiatives Supporting Researchers Across NIH

scientists talking in a lab

From Superbowl-winning football teams to comic book cohorts like The Avengers, combining the efforts of multiple talented individuals is a proven strategy for achieving remarkable results. It may come as no surprise, then, that the NIH’s Intramural Research Program (IRP) strongly encourages collaborations that breach the boundaries of its 24 Institutes and Centers. One example of these efforts is the Director’s Challenge Innovation Awards Program, which since 2009 has funded high-impact scientific projects that bring together researchers from across the IRP.

Synthetic Antibody Rallies Immune Cells Against Ovarian Cancer

Study Also Reveals Immunotherapy’s Target on Cancer Cells

antibodies

In the 1995 film The Usual Suspects, Kevin Spacey’s con man character famously remarks, “The greatest trick the Devil ever pulled was convincing the world he didn't exist.” The same could be said of cancer, which somehow persuades the body it is not a threat. Cutting-edge treatments called immunotherapies remove this façade and encourage the immune system to attack cancer cells. New IRP research in mice has demonstrated the promise of a new immunotherapy for treating ovarian cancer and identified a marker on cancer cells that could help clinicians identify patients who are most likely to benefit from the therapy.

Remembrances: Flossie Wong-Staal

Dr. Flossie Wong-Staal

Flossie Wong-Staal — a pioneering former NIH scientist, a major figure in the discovery of HIV, and the first to clone that virus — died on July 8, 2020. She was 73 years old.

Flossie arrived at the NIH as a Visiting Fellow in 1973 and began working in the National Cancer Institute (NCI) lab of Robert Gallo, who was on the cusp of a remarkable string of discoveries. Flossie, with her Ph.D. from UCLA in molecular biology, became the ideal complement to Bob Gallo's medical-based scientific intuition, and the two would go on to co-author more than 100 journal articles over the next 20 years.

IRP’s Andre Nussenzweig Elected to National Academy of Medicine

NIH Researcher Recognized for Investigation into Genomic Stability

Dr. Andre Nussenzweig

The National Academy of Medicine (NAM), first established in 1970 by the National Academy of Sciences as the Institute of Medicine (IOM), is comprised of more than 2,000 elected members from around the world who provide scientific and policy guidance on important matters relating to human health. Election to the NAM is considered one of the highest honors in the fields of health and medicine and recognizes individuals who have not only made critical scientific discoveries but have also demonstrated a laudable commitment to public service.

IRP senior investigator Andre Nussenzweig, Ph.D., was one of four IRP researchers recently elected to the NAM. Dr. Nussenzweig leads the Laboratory of Genome Integrity at the National Cancer Institute (NCI), where he studies how cells repair a form of DNA damage called a double strand break (DSB). This type of insult, which severs both strands of the double-stranded DNA molecule, is one of the most dangerous. If not repaired properly, DSBs can kill cells or cause DNA to rearrange in ways that are associated with cancer. Moreover, while DSBs can be caused by chemotherapy drugs and radiation, they can also happen by random chance during the course of normal cellular processes. Intriguingly, not all parts of the DNA molecule are equally susceptible to this form of damage.

Gene Editing Reveals Potential Cancer Treatment Target

Scientists Parse Wide-Ranging Effects of Endometrial Cancer Mutation

a piece of DNA being removed from a DNA molecule

The so-called ‘butterfly effect’ supposes that a butterfly flapping its wings in Brazil can cause a tornado in Texas. While the jury is still out on insect-induced natural disasters, it is clear that a single genetic mutation can have wide-ranging and unexpected consequences throughout a cell. By examining the ripple effects caused by changes in a particular gene, IRP researchers have identified a potential treatment target for a particularly deadly variety of cancer.

Statins May Guard Hearing from Deafening Cancer Chemotherapy

Mouse Study Suggests Approach to Protect Cancer Patients’ Hearing

ear

The internet is filled with lists of ‘life hacks’ that provide instructions on how to re-purpose common items, from turning glass jars into flower vases to using sticky notes to remove dust or crumbs from the crevices of a computer keyboard. On occasion, this kind of inventive spirit can be used to improve human health as well. IRP researchers have found evidence in mice that a statin medication originally created to lower cholesterol might also reduce hearing loss caused by a common cancer therapy.

Research Symposium Celebrates Graduate Student Science

Event Spotlights Students Completing Their Ph.D. Research in IRP Labs

NIH graduate student John Fenimore

The NIH provides an extraordinarily rich environment for learning and honing the skills needed to pursue a scientific career. It’s no wonder, then, that Ph.D. students from institutions all across the United States and the rest of the world come here to conduct their dissertation research under the mentorship of the IRP’s many renowned investigators.

Nearly 150 of those students presented the fruits of their scientific work at the NIH’s 16th annual Graduate Student Research Symposium on Thursday, February 20. The insights they have produced on topics from cancer to autoimmune disease to environmental contaminants were supremely impressive and will likely contribute to important improvements in medical care in the future. For anyone who missed this exciting event, read on to learn about a few of the many research projects that were on display.

Cancer Therapy May Drain Cellular Batteries

Decreased Energy Production Could Contribute to Cancer-Related Fatigue

tired man rubbing his eyes

We all know the feeling of being wiped out after a hard workout or a grueling day at the office — you just want to flop down on the couch and not move, or even think. For many cancer patients, the treatment for their disease can trigger that sort of physical and mental exhaustion for weeks or months. New IRP research has found evidence linking this phenomenon, known as cancer-related fatigue, to a slow-down in cells’ energy-producing mitochondria.

Remembrances: Phil Leder (1934-2020)

Phil Leder at a chalkboard

Our friend and former colleague Phil Leder, among the world's most accomplished molecular geneticists, died on Sunday, February 2, at age 85. His work with Marshall Nirenberg — namely, the famed Nirenberg and Leder experiments starting at the NIH in 1964, which definitively elucidated the triplet nature of the genetic code and culminated in its full deciphering — helped set the stage for the revolution in molecular genetic research that Phil himself would continue to lead for the next three decades.

A Country-Spanning Cancer Collaboration

Scientific Team-Up Identifies Source of Tumor Drug Resistance

acute myeloid leukemia cells

It’s an unfortunate reality that nearly everyone knows somebody whose life has been affected by cancer. However, a discovery by two researchers who met by chance years ago might one day help more cancer patients overcome their disease. Two scientific teams led by the IRP’s Craig Thomas, Ph.D., a group leader at the NIH’s National Center for Advancing Translational Sciences (NCATS), and Daniel Starczynowski, Ph.D., of Cincinnati Children’s Hospital Medical Center, recently published a study describing a possible breakthrough in the fight against acute myeloid leukemia (AML), a form of cancer responsible for nearly 11,000 deaths per year in the United States.